PanTher Completes First Cohort in Pancreatic Cancer Phase 1b Trial Ahead of Expectations
– Trial evaluating PTM-101, an absorbable, long-lasting, high-dose chemotherapy patch for non-metastatic pancreatic cancer –
– PTM-101 administration in the 200 mg cohort has been completed without dose-limiting toxicity –
– First subject enrolled in highest cohort of dose escalation phase, and enrollment ongoing across the U.S. –
AUSTIN, Texas–(BUSINESS WIRE)–PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage company redefining cancer treatment with therapeutics administered continuously and exclusively at the tumor site, today announced that it has concluded dosing in the first cohort of its Phase 1b clinical trial of PTM-101 in pancreatic ductal adenocarcinoma (PDAC). The rapid completion of this middle-dose cohort reflects vigorous engagement of the clinical oncology community with this new approach to cancer treatment.
The ongoing dose escalation and expansion study builds on findings from PanTher’s first-in-human trial that confirmed the safety of PTM-101 at 100 mg and reported promising tumor shrinkage. In the current U.S. Phase 1b trial, patients are being treated at escalating dose levels of 200 mg and 400 mg. Completion of the full cohort at the 200 mg dose level without evidence of toxicities further demonstrates PTM-101’s safety — even at a dose higher than what is typically used for IV infusion — and confirms its ability to be administered with well-established laparoscopic procedures. The Safety Committee has cleared advancement to the final anticipated cohort, and dosing at the 400 mg dose level has now begun, with the first patient treated.
